Less than a year after a scandal embroiled its then China boss, pharma group AstraZeneca appears to have bounced back, maintaining sales and avoiding major fallout in the country.
在原manbetx3.0 区总裁卷入丑闻不到一年后，制药巨头阿斯利康(AstraZeneca)在manbetx3.0 似乎已重整旗鼓，还能保持原来的销售额，避免了重大负面影响。
您已阅读3%（249字），剩余97%（6971字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。